Elicio Therapeutics

Q1 FY2026 EarningsQ2 FY26 results beat consensus on the bottom line, with a GAAP EPS loss of $0.43 vs. the $0.54 loss expected. While the Phase 2 AMPLIFY-7P trial failed to meet its primary endpoint, management's strategic shift toward combination therapies and a recent $15M financing extension of the cash runway into Q1 2027 provided some stability. Operating expenses were lower than anticipated, driven by reduced clinical trial costs as the lead program transitioned into a follow-up phase.